621 reports of this reaction
2.7% of all FREMANEZUMAB VFRM reports
#6 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #6 most commonly reported adverse reaction for FREMANEZUMAB VFRM, manufactured by Teva Pharmaceuticals USA, Inc.. There are 621 FDA adverse event reports linking FREMANEZUMAB VFRM to INJECTION SITE ERYTHEMA. This represents approximately 2.7% of all 22,887 adverse event reports for this drug.
Patients taking FREMANEZUMAB VFRM who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for FREMANEZUMAB VFRM, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for FREMANEZUMAB VFRM:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 621 FDA reports for FREMANEZUMAB VFRM. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 2.7% of all adverse event reports for FREMANEZUMAB VFRM, making it a notable side effect.
If you experience injection site erythema while taking FREMANEZUMAB VFRM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.